These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27913395)

  • 1. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of 1-Methylnicotinamide as a specific biomarker for the progression of cirrhosis to hepatocellular carcinoma.
    Zhang S; Tuo P; Ji Y; Huang Z; Xiong Z; Li H; Ruan C
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):310. PubMed ID: 38890166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma.
    Han J; Han ML; Xing H; Li ZL; Yuan DY; Wu H; Zhang H; Wang MD; Li C; Liang L; Song YY; Xu AJ; Wu MC; Shen F; Xie Y; Yang T
    Int J Cancer; 2020 Mar; 146(6):1741-1753. PubMed ID: 31361910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.
    Luo P; Yin P; Hua R; Tan Y; Li Z; Qiu G; Yin Z; Xie X; Wang X; Chen W; Zhou L; Wang X; Li Y; Chen H; Gao L; Lu X; Wu T; Wang H; Niu J; Xu G
    Hepatology; 2018 Feb; 67(2):662-675. PubMed ID: 28960374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
    Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA
    World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
    Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
    Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis.
    Ressom HW; Xiao JF; Tuli L; Varghese RS; Zhou B; Tsai TH; Ranjbar MR; Zhao Y; Wang J; Di Poto C; Cheema AK; Tadesse MG; Goldman R; Shetty K
    Anal Chim Acta; 2012 Sep; 743():90-100. PubMed ID: 22882828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis.
    Dai W; Yin P; Chen P; Kong H; Luo P; Xu Z; Lu X; Xu G
    Anal Bioanal Chem; 2014 Jul; 406(18):4325-35. PubMed ID: 24817358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry.
    Zeng J; Yin P; Tan Y; Dong L; Hu C; Huang Q; Lu X; Wang H; Xu G
    J Proteome Res; 2014 Jul; 13(7):3420-31. PubMed ID: 24853826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
    Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
    PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
    Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
    PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma.
    Ge T; Shen Q; Wang N; Zhang Y; Ge Z; Chu W; Lv X; Zhao F; Zhao W; Fan J; Qin W
    Med Oncol; 2015 Mar; 32(3):59. PubMed ID: 25652109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.
    Shen Q; Fan J; Yang XR; Tan Y; Zhao W; Xu Y; Wang N; Niu Y; Wu Z; Zhou J; Qiu SJ; Shi YH; Yu B; Tang N; Chu W; Wang M; Wu J; Zhang Z; Yang S; Gu J; Wang H; Qin W
    Lancet Oncol; 2012 Aug; 13(8):817-26. PubMed ID: 22738799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables.
    Wang M; Mehta A; Block TM; Marrero J; Di Bisceglie AM; Devarajan K
    BMC Med Genomics; 2013; 6 Suppl 3(Suppl 3):S9. PubMed ID: 24564861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Han J; Qin WX; Li ZL; Xu AJ; Xing H; Wu H; Zhang H; Wang MD; Li C; Liang L; Quan B; Yan WT; Shen F; Wu MC; Yang T
    Clin Chim Acta; 2019 Jan; 488():68-75. PubMed ID: 30389456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.